FDA warns labs about Thermo Fisher TaqPath COVID-19 kit

By LabPulse.com staff writers

August 17, 2020 -- The U.S. Food and Drug Administration (FDA) on August 17 issued a warning to clinical labs about false results that could be generated from Thermo Fisher Scientific's TaqPath combo kit for COVID-19.

The FDA said the erroneous results could be generated by the TaqPath combo kit under certain circumstances. The kit is a molecular assay that's used with associated Applied Biosystems COVID-19 interpretive software for detecting COVID-19 using respiratory specimens.

The first issue concerns inadequate vortexing and centrifugation of reverse transcription polymerase chain reaction (RT-PCR) reaction plates, which could lead to false-positive results. After investigating customer complaints, Thermo Fisher has updated its instructions to reduce the risk of false positives.

The FDA said that the second issue is related to the assay's internal positive control. A fix requires lab staff to upgrade their software to lower the risk of invalid, potentially false-negative results, as well as inconclusive tests that could create the potential need to perform retesting.

The FDA made a number of recommendations on its website, including advising that clinical labs implement software updates and instructions from Thermo Fisher, in particular by upgrading the Applied Biosystems COVID-19 software to version 1.3 or 2.3. More information is available on Thermo Fisher's website.

Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...
Thermo Fisher posts 10% growth in Q2
Thermo Fisher Scientific reported financial results for the second quarter, noting 10% revenue growth.
Thermo Fisher expands COVID-19 therapies, vaccines
Thermo Fisher Scientific is expanding the development and production of COVID-19 vaccines, therapies, and additional treatments.
Thermo Fisher increases Qiagen acquisition offer
Thermo Fisher Scientific and Qiagen have amended their acquisition agreement with an increase from the original offer price of 39 euros ($44.61 U.S.)...
Thermo Fisher launches Smart-Vue Pro remote monitoring system
Thermo Fisher Scientific has unveiled Smart-Vue Pro, a new remote monitoring system for laboratory equipment.

Copyright © 2020 LabPulse.com

Last Updated ls 8/17/2020 3:59:21 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current